AdvisorShares Pure US Cannabis ETF

MSOS | NYSE Arca, Inc.

Annual Shareholder Report | JUNE 30, 2026

This annual shareholder report contains important information about AdvisorShares Pure US Cannabis ETF (the "Fund") for the period of July 1, 2025 to June 30, 2026. You can find additional information about the Fund at https://www.advisorshares.com/about/literature-center. You can also request this information by contacting us at 1-877-843-3831.

What were the Fund’s costs for the period?

(based on a hypothetical $10,000 investment)

Fund	Cost of $10K Investment	Cost Paid as % of $10K Investment
AdvisorShares Pure US Cannabis ETF	$113	0.72%

Management's Discussion of Fund Performance

MSOS experienced gains during the fiscal year ended June 30, 2026.The year marked a significant shift for the U.S. cannabis sector following years of anticipation around federal rescheduling. On April 23, 2026, the Department of Justice issued a Final Order rescheduling cannabis subject to a state medical license, and cannabis in FDA-approved drug products, from Schedule I to Schedule III of the Controlled Substances Act. The DOJ also directed the DEA to restart formal rulemaking to consider broader rescheduling of adult-use cannabis, with an expedited administrative hearing scheduled to begin June 29, 2026. Adult-use cannabis remains classified as a Schedule I substance under federal law, while its legal status and regulation are determined at the state level.

The rescheduling removed affected state-licensed operators from the reach of Section 280E of the Internal Revenue Code, which had previously disallowed standard business tax deductions for companies trafficking in Schedule I or II substances, easing a longstanding tax burden on the industry. The Department of the Treasury and Internal Revenue Service subsequently indicated that further guidance on the resulting tax treatment would follow.

These developments coincided with continued growth in state-level cannabis sales and contributed to improved market sentiment and capital markets activity across the sector, including the first uplistings of U.S. listed cannabis companies to the NYSE. Price competition and market fragmentation at the state level remained ongoing considerations for the industry during the period. The Fund uses total return swap derivative contracts with multiple counterparties, representing more than 70% of its total assets, to gain exposure to cannabis stocks the Fund cannot hold directly. The Fund does not use derivatives for leverage or hedging. While the swaps do have fees, they represent the performance of their underlying stocks and do not otherwise add or detract from the Fund’s performance.

The Fund uses total return swap derivative contracts with multiple counterparties, representing more than 70% of its total assets, to gain exposure to cannabis stocks that the Fund cannot hold directly. The Fund does not use derivatives for leverage or hedging. While the swaps do have fees, they represent the performance of their underlying stocks and do not otherwise add or detract from the Fund’s performance.

Fund Performance

GROWTH OF AN ASSUMED $10,000 INVESTMENT



AVERAGE ANNUAL TOTAL RETURN

Fund/Index	1 year	5 year	Since Inception 9/1/2020
AdvisorShares Pure US Cannabis ETF NAV	113.68%	-33.82%	-23.86%
S&P 500 Index	22.32%	13.41%	15.49%

The fund's past performance is not a good predictor of how the fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares. Current performance may be lower or higher than the performance data quoted. Investment return and principal value will fluctuate so that an investor's shares, when redeemed, may be worth more or less than original cost. Fund NAV returns are calculated using the Fund's daily 4:00 p.m. NAV. Returns shown include the reinvestment of all dividends and other distributions. Index returns do not include expenses. Returns less than one year are not annualized. The performance table and graph do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or the redemption of Fund shares. For the Fund's most recent month end performance, please call 1-877-843-3831.

Key Fund Statistics

The following table outlines key fund statistics as of 6/30/2026.

Fund net assets	$1,047,407,492
Total advisory fees paid	$5,015,433
Total number of portfolio holdings	61
Period portfolio turnover rate	5%

Portfolio Composition

The table below shows the investment makeup of the Fund as of 6/30/2026. This does not represent the Fund's market exposure due to the exclusion of derivatives.

Sector	% of Net Assets
Agriculture	0.3%
Household & Personal Products	0.9%
Pharmaceuticals	24.6%
Money Market Funds	5.8%
Assets Less Liabilities	68.4%
Total	100.0%

Availability of Additional Information

If you wish to find additional information about the Fund such as the prospectus, financial information, portfolio holdings and proxy voting, please see the website address or contact number included at the beginning of this shareholder report.